Trivanga Bhasma: Traditional Uses, Evidence & Safety

TL;DR

Trivanga bhasma is a classical herbo-mineral of calcined tin, lead, and zinc, traditionally used for prameha (urinary disorders) and as a reproductive tonic. Animal toxicity studies report no harm at therapeutic-equivalent doses, with liver and kidney changes only at ten times the dose. No human efficacy trial exists. It contains lead: read the safety section with full attention.

What it is

Trivanga means "three metals": the formulation combines the bhasmas (calcined ashes) of vanga (tin), naga (lead), and yashada (zinc), prepared through repeated purification and incineration cycles. The batch attributes record it as bitter and astringent, light and dry, heating, pacifying kapha and pitta while aggravating vata, with pramehaghna (anti-prameha) and vrishya (aphrodisiac) actions. It is one of the more potent Rasa Shastra preparations, and its lead content defines every safety discussion about it.

Traditional use

Classical texts prescribe trivanga bhasma for prameha (a group of urinary disorders correlated with diabetes and related metabolic conditions), urinary tract disorders, debility, and as a vrishya (reproductive tonic). These are traditional claims, not clinical proof. The research record is examined separately below, and the two are not the same thing.

What modern research says

Sub-chronic toxicity in mice

A 90-day toxicity study published in AYU administered trivanga bhasma to mice and evaluated behavioral, hematological, biochemical, and histopathological parameters. It reads as a formal safety assessment (AYU 2013, PDF).

28-day repeated-dose study in rats

A 28-day repeated oral dose study in rats found no significant toxicity at the therapeutic-equivalent dose. Liver and kidney changes appeared only at ten times that dose — a margin between the classical dose and the dose where harm shows up in rats (IJPSR full text).

What the evidence does not support (yet)

No human trial supports trivanga bhasma for diabetes, urinary disorders, or reproductive function. Animal toxicity data are not efficacy data, and a safety margin in rats is not a safety guarantee in people, particularly for a lead-containing medicine taken over time.

Safety & contraindications

Read this carefully. Trivanga bhasma contains lead. Lead accumulates in the body, and chronic lead exposure damages the nervous system, kidneys, and blood formation; children and pregnant women are the most vulnerable. The animal studies above are reassuring only at classical-equivalent doses and short durations. This medicine should be used only as a licensed, quality-tested product, only under a qualified practitioner, never in pregnancy or childhood, never long-term without supervision, and never alongside other lead- or heavy-metal-containing preparations. If you take it, periodic monitoring as advised by your clinician is common sense, not optional.

FAQs

What is trivanga bhasma?

A classical Ayurvedic preparation combining the calcined ashes of tin, lead, and zinc, used traditionally for urinary and metabolic disorders.

What is trivanga bhasma used for in Ayurveda?

Traditionally for prameha (urinary/metabolic disorders including diabetes), urinary tract complaints, and as a reproductive tonic. Traditional uses, not clinically proven effects.

Does research support it for diabetes?

No. The published modern studies are animal toxicity studies, not efficacy trials. No human trial exists.

The animal studies found it safe. Does that mean it is safe for me?

No. A safety margin in rats over 28–90 days does not establish safety in humans, especially for a lead-containing drug that could be taken for months. Human safety data do not exist.

Can it be taken in pregnancy or by children?

No. Lead is a known developmental toxicant. Avoid completely.

Classical texts specify small doses, but there is no modern human dose-ranging evidence. No recommendation can be made here; use only under a qualified practitioner with a licensed, tested product.

Sources

The 90-day mouse toxicity study appears in AYU 34(1), 2013 (PDF). The 28-day repeated-dose rat study, which found hepatic and renal changes only at ten times the therapeutic-equivalent dose, is published in the International Journal of Pharmaceutical Sciences and Research (full text). Traditional indications follow standard Rasa Shastra descriptions of trivanga as pramehaghna and vrishya. The lead-toxicity warnings reflect established toxicology, not any single cited paper. No human efficacy trial was identified in the searches conducted for this article.

Disclaimer

This article is for educational purposes only and is not medical advice. Trivanga bhasma contains lead and must only be used as a licensed, quality-tested product under qualified supervision. Never use it in pregnancy or childhood, never attempt home preparation, and never combine it with other metal-containing medicines without medical oversight. Talk to a qualified healthcare practitioner before use.